Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Interest Receivables (2024 - 2025)

SAB Biotherapeutics' Change in Interest Receivables history spans 2 years, with the latest figure at $386827.0 for Q4 2025.

  • For Q4 2025, Change in Interest Receivables rose 1019.0% year-over-year to $386827.0; the TTM value through Dec 2025 reached $891826.0, up 1522.83%, while the annual FY2025 figure was $891826.0, 1522.83% up from the prior year.
  • Change in Interest Receivables reached $386827.0 in Q4 2025 per SABSW's latest filing, down from $559954.0 in the prior quarter.
  • In the past five years, Change in Interest Receivables ranged from a high of $559954.0 in Q3 2025 to a low of -$127877.0 in Q3 2024.